SLI
2.114,32
PKT
+16,71
PKT
+0,80
%
Werbung
Analysen zu SLI-Werten
Datum | Rating | Analyst | |
---|---|---|---|
06.02.19 | ams-OSRAM Hold | Hauck & Aufhäuser Privatbankiers KGaA | |
06.02.19 | Novartis Hold | HSBC | |
06.02.19 | Holcim overweight | JP Morgan Chase & Co. | |
05.02.19 | Zurich Insurance Neutral | JP Morgan Chase & Co. | |
05.02.19 | ams-OSRAM buy | Kepler Cheuvreux | |
05.02.19 | ams-OSRAM overweight | Barclays Capital | |
05.02.19 | ams-OSRAM Neutral | UBS AG | |
05.02.19 | ams-OSRAM Neutral | JP Morgan Chase & Co. | |
05.02.19 | ams-OSRAM Underperform | Credit Suisse Group | |
04.02.19 | Zurich Insurance buy | Merrill Lynch & Co., Inc. | |
04.02.19 | Roche buy | Jefferies & Company Inc. | |
04.02.19 | UBS buy | UBS AG | |
04.02.19 | UBS buy | Deutsche Bank AG | |
04.02.19 | Roche Reduce | HSBC | |
04.02.19 | Holcim Hold | HSBC | |
04.02.19 | Novartis Hold | Deutsche Bank AG | |
01.02.19 | Roche Reduce | HSBC | |
01.02.19 | Zurich Insurance Neutral | UBS AG | |
01.02.19 | Swiss Re Sell | UBS AG | |
01.02.19 | Givaudan Sell | Goldman Sachs Group Inc. | |
01.02.19 | Novartis Underweight | Barclays Capital | |
01.02.19 | ams-OSRAM overweight | Barclays Capital | |
01.02.19 | Roche Neutral | Credit Suisse Group | |
01.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
31.01.19 | Roche Neutral | UBS AG | |
31.01.19 | Roche Hold | Deutsche Bank AG | |
31.01.19 | Novartis Neutral | Credit Suisse Group | |
31.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
31.01.19 | Roche overweight | JP Morgan Chase & Co. | |
31.01.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
31.01.19 | Roche buy | Jefferies & Company Inc. | |
30.01.19 | ams-OSRAM Underperform | Credit Suisse Group | |
30.01.19 | Novartis Hold | Deutsche Bank AG | |
30.01.19 | Nestlé overweight | JP Morgan Chase & Co. | |
30.01.19 | Roche buy | Goldman Sachs Group Inc. | |
30.01.19 | Novartis Neutral | UBS AG | |
30.01.19 | Novartis buy | Kepler Cheuvreux | |
30.01.19 | Roche Neutral | UBS AG | |
30.01.19 | Zurich Insurance Hold | Jefferies & Company Inc. | |
30.01.19 | Novartis buy | Jefferies & Company Inc. |